


# Evaluation de la réponse thérapeutique

Tumeurs  
hématologiques



Tumeurs solides



# Comment ?

## Measurement of Clinical and Subclinical Tumour Response Using [<sup>18</sup>F]-fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations

H. Young,<sup>1</sup> R. Baum,<sup>2</sup> U. Cremerius,<sup>3</sup> K. Herholz,<sup>4</sup> O. Hoekstra,<sup>5</sup> A.A. Lammertsma,<sup>5</sup>  
J. Pruijm<sup>6</sup> and P. Price<sup>1</sup> on behalf of the European Organization for Research and Treatment  
of Cancer (EORTC) PET Study Group

Eur J Cancer, Vol. 35, No. 12, pp. 1772–1782, 1999

## Consensus Recommendations for the Use of <sup>18</sup>F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials

Lalitha K. Shankar<sup>1</sup>, John M. Hoffman<sup>2</sup>, Steve Bacharach<sup>3</sup>, Michael M. Graham<sup>4</sup>, Joel Karp<sup>5</sup>, Adriaan A. Lammertsma<sup>6</sup>, Steven Larson<sup>7</sup>, David A. Mankoff<sup>8</sup>, Barry A. Siegel<sup>9</sup>, Annick Van den Abbeele<sup>10</sup>, Jeffrey Yap<sup>10</sup>, and Daniel Sullivan<sup>1</sup>

THE JOURNAL OF NUCLEAR MEDICINE • Vol. 47 • No. 6 • June 2006

Dr Julien  
Dubreuil

## From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Richard L. Wahl<sup>1,2</sup>, Heather Jacene<sup>1</sup>, Yvette Kasamon<sup>2</sup>, and Martin A. Lodge<sup>1</sup>

<sup>1</sup>Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and

<sup>2</sup>Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland

# Pour Qui ?

**Use of [<sup>18</sup>F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [<sup>18</sup>F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial**

Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Pierre Kerbrat, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Sylvia Giard, David Coeffic, Philippe Bougnoux, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Juana Hernandez, Mathieu Coudert, Laurent Arnould, Alina Berriolo-Riedinger



## Modèle néoadjuvant

The  
**Oncologist<sup>®</sup>**

Breast Cancer

### Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer


OLIVIER HUMBERT,<sup>a,c,d</sup> ALEXANDRE COCHET,<sup>a,d</sup> BRUNO COUDERT,<sup>b</sup> ALINA BERRIOLLO-RIEDINGER,<sup>a</sup> SALIM KANOUN,<sup>a</sup> FRANÇOIS BRUNOTTE,<sup>a,c</sup> PIERRE FUMOLEAU<sup>b</sup>

Departments of <sup>a</sup>Nuclear Medicine and <sup>b</sup>Medical Oncology, Centre G.F. Leclerc, Dijon, France; <sup>c</sup>Imaging Department, Centre Hospitalo-Universitaire Le Bocage, Dijon, France; <sup>d</sup>Université de Bourgogne, UMR CNRS 6306, Dijon, France  
*Disclosures of potential conflicts of interest may be found at the end of this article.*

**Key Words.** Breast • Cancer • Positron emission tomography • <sup>18</sup>F-Fluorodeoxyglucose • Response • Monitoring

**Dr Olivier Humbert**  
**Dr MA Mouret Reyner**

# Perspectives



## Immunothérapie?

### Predictive value of early $^{18}\text{F}$ -FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study

Christos Sachpekidis · Lionel Larribere · Leyun Pan ·  
Uwe Haberkorn · Antonia Dimitrakopoulou-Strauss ·  
Jessica C. Hassel

Received: 11 August 2014 / Accepted: 15 October 2014

Pr Frédéric Courbon